Health CarePharmaceuticals & Biotechnology
  • Price (USD)115.10
  • Today's Change0.00 / 0.00%
  • Shares traded30.00
  • 1 Year change0.33%
  • Beta0.1584
Data delayed at least 15 minutes, as of Nov 19 2019 23:30 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

  • Revenue in USD (TTM)22.64bn
  • Net income in USD4.44bn
  • Incorporated1901
  • Employees38.68k
  • Location
    Eli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
  • Phone+1 (317) 276-2000
  • Fax+1 (317) 276-3492
  • Websitehttps://www.lilly.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LLY:NYQ since
Loxo Oncology IncDeal completed07 Jan 201907 Jan 2019Deal completed0.38%7.99bn
Data delayed at least 15 minutes, as of Nov 19 2019 23:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Vertex Pharmaceuticals Incorporated3.62bn583.76m55.29bn2.50k95.7810.5384.0015.272.248.2513.9220.420.59663.398.801,447,865.009.21-5.1111.49-6.6586.6088.1815.43-8.993.32402.490.0992--22.4620.25103.80--13.20--
Zoetis Inc6.15bn1.47bn57.31bn10.00k39.4121.4230.529.323.053.0312.745.620.5661.386.28615,000.0013.5710.6514.9812.7567.7466.0523.9716.423.029.620.706523.639.765.0128.5322.3712.9320.91
Allergan plc15.82bn-9.27bn60.80bn16.90k--1.04--3.84-27.89-27.8547.82178.220.15742.405.42935,952.70-9.21-3.61-10.01-3.8984.9783.23-58.53-28.240.8830.00420.278---0.961743.4124.17---3.81--
Celgene Corporation16.98bn5.80bn76.96bn8.85k13.496.3611.924.538.028.1323.5016.990.44941.307.561,918,437.0015.3510.8817.3512.1296.3195.9434.1624.472.806.520.62080.0017.5218.67-4.8922.5218.86--
Gilead Sciences, Inc.22.37bn2.71bn82.23bn11.00k30.883.9920.043.682.112.0917.4716.270.36235.376.602,033,182.004.3623.085.2028.2279.6084.3712.0443.522.876.070.542517.01-15.2414.59-46.0612.1737.10--
Bristol-Myers Squibb Co24.17bn5.66bn92.02bn23.30k16.325.2114.313.813.463.4614.7710.830.53035.705.431,037,468.0012.4710.0516.0713.9270.8573.8723.5217.903.7219.210.584374.948.596.6127.4914.1912.112.71
Eli Lilly And Co22.64bn4.44bn110.51bn38.68k24.7832.6919.464.884.648.2123.543.520.54881.394.36585,421.4010.776.4814.889.0077.7874.0119.6211.690.882922.100.814787.087.361.2299.27-6.1722.522.80
AbbVie Inc32.87bn3.32bn131.64bn30.00k39.86--24.854.012.232.1822.17-5.560.52334.075.811,095,567.005.329.307.2112.1277.0177.2410.1718.821.045.551.2783.7616.0811.751.066.835.3817.54
Amgen, Inc.23.40bn8.07bn133.39bn21.50k17.2312.2513.265.7013.0313.0337.7518.330.36881.346.641,088,140.0012.729.9615.5611.4282.0581.1534.4832.602.5914.980.731640.323.934.923.9010.561.2722.94
Data as of Nov 19 2019. Currency figures normalised to Eli Lilly and Co's reporting currency: US Dollar USD

Institutional shareholders

32.46%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 201969.71m7.26%
PRIMECAP Management Co.as of 30 Sep 201942.83m4.46%
BlackRock Fund Advisorsas of 30 Sep 201941.87m4.36%
Wellington Management Co. LLPas of 30 Sep 201939.66m4.13%
SSgA Funds Management, Inc.as of 30 Sep 201937.11m3.87%
Capital Research & Management Co. (International Investors)as of 30 Sep 201925.15m2.62%
State Farm Investment Management Corp.as of 30 Sep 201919.94m2.08%
Fidelity Management & Research Co.as of 30 Sep 201912.22m1.27%
Geode Capital Management LLCas of 30 Sep 201912.15m1.27%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 201911.04m1.15%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.